'Boceprevir' diaporamas de présentation

Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions

Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions. C Kasserra, E Hughes, M Treitel, S Gupta, and E O'Mara International Conference on Viral Hepatitis April 11, 2011 Baltimore, MA. Disclosure Statement. Full time employee of Merck and Co.

185 views • 17 slides

T. Poynard , MD

272 views • 16 slides

SPRINT-1 Study Design

PART 1. PART 2 a. SPRINT-1 Study Design. Week 28. Week 4. Week 48. Peg-IFN ? 2b 1.5 ? g/kg + RBV 800-1400 mg for 48 wks . 24 wks Follow-up. N=104. Control. 44 wks Follow-up. Peg-IFN ? 2b + RBV 800-1400 mg. Peg-IFN ? 2b 1.5 ? g/kg + RBV 800-1400mg +

269 views • 1 slides